Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Aug 3;7:7172. doi: 10.1038/s41598-017-07482-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Peptide-protein and Peptide-Protein-DNA interactions of the TAT/NLS/EWS-PEP peptide. (A) Western blot analysis of ectopically expressed FLAG/EWS-FLI1 expression in MCF-7 cell lysates. Lanes 1: lysate from vector alone expressing cells, and 2: Lysate from FLAG/EWS-FLI1 expressing cells. Upper panel blot was probed with anti-FLAG mouse monoclonal antibody, and the lower panel shows the same blot reprobed with mouse monoclonal anti-GAPDH antibody. (B) Detecting TAT/NLS/EWS-PEP in FLAG immunoprecipitates (IP) using western blot: Lanes 1–4: 1: Bead control, 2: IP from MCF-7 empty vector expressing cells, 3: IP from MCF-7 empty vector expressing cells in the presence of TAT/NLS/EWS-PEP, and 4: IP from MCF-7 FLAG/EWS-FLI1 expressing cells and 5: IP from MCF-7 FLAG/EWS-FLI1 expressing cells in the presence of TAT/NLS/EWS-PEP. Full length blots are displayed in the figure. (C) EWS-FLI1 EMSA using 7XGGAA duplex probe. TAT/NLS peptide interaction with 7XGGAA probe. Lane 1(from right): probe alone, Lane 2: probe and A673 N.E., Lanes 3 to 7: probe with TAT/NLS at increasing concentrations (1, 2, 4, 8 and 10 μM). (D) EWS-FLI1 EMSA using 7XGGAA duplex probe. TAT/NLS/EWS-PEP peptide interaction with 7XGGAA probe. Lanes 1: probe alone, 2: probe and A673 N.E., Lanes 3 to 7 probe with TAT/NLS/EWS-PEP at increasing concentrations (1, 2, 4, 8 and 10 μM). (E) EWS-FLI1 EMSA using 7XGGAA duplex probe. TAT/NLS peptide interaction with 7xGGAA probe in presence of A673 N.E. Lane 1: probe alone, Lane 2: probe and A673 N.E, Lanes 3 to 7 mixture of probe with A673 N.E. and TAT/NLS at increasing concentrations (1, 2, 4, 8 and 10 μM). (F) EWS-FLI1 EMSA using 7XGGAA duplex probe. TAT/NLS/EWS-PEP peptide interaction with 7XGGAA probe in presence of A673 N.E., Lane 1: probe alone, Lane 2: probe and A673 N.E., Lane 3 to 7 mixture of probe with A673 N.E., andTAT/NLS/EWS-PEP at increasing concentrations (1, 2, 4, 8 and 10 μM).